We are live on ! Find out more
CASC

Cascadian Therapeutics, Inc.
CASC

Delisted

CASC was delisted on the 8th of March, 2018.

Back to rankings

100 hedge funds and large institutions have $211M invested in Cascadian Therapeutics, Inc. in 2015 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 38 increasing their positions, 22 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

105% more capital invested

Capital invested by funds: $103M → $211M (+$108M)

73% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 22

72% more call options, than puts

Call options by funds: $2.99M | Put options by funds: $1.74M

59% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 17

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

11% more funds holding

Funds holding: 90 → 100 (+10)

Holders
100
Holders Change
+10
Holders Change %
+11.11%
% of All Funds
2.69%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.08%
New
27
Increased
38
Reduced
22
Closed
17
Calls
$2.99M
Puts
$1.74M
Net Calls
+$1.25M
Net Calls Change
+$1.25M

Top Buyers

Rank Fund Capital Flow
1
RG
Redmile Group
California
+$11M
2
PA
Perceptive Advisors
New York
+$6.38M
3
ACA
Avoro Capital Advisors
New York
+$2.97M
4
ACP
Acuta Capital Partners
California
+$1.77M
5
State Street
State Street
Massachusetts
+$1.16M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$12M
2
QF
QVT Financial
New York
-$10.2M
3
BC
Broadfin Capital
New York
-$4.75M
4
First Eagle Investment Management
First Eagle Investment Management
New York
-$2.12M
5
RCM
RA Capital Management
Massachusetts
-$1.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
101
Candriam SCA
Luxembourg
– -$1.21M -123,333 Closed
Point72 Asset Management
102
Point72 Asset Management
Connecticut
– -$1.02M -104,167 Closed
SM
103
Sabby Management
Florida
– -$681K -69,659 Closed
WMSA
104
Weiss Multi-Strategy Advisers
New York
– -$348K -35,583 Closed
MIM
105
Monashee Investment Management
Massachusetts
– -$326K -33,333 Closed
DM
106
Deerfield Management
New York
– -$233K -23,867 Closed
ZIM
107
Zacks Investment Management
Illinois
– -$161K -16,424 Closed
HCM
108
Highlander Capital Management
New Jersey
– -$90K -9,167 Closed
AL
109
Airain Ltd
Guernsey
– -$59K -5,988 Closed
FAAS
110
First Allied Advisory Services
California
– -$33K -3,333 Closed
OAM
111
Oxford Asset Management
United Kingdom
– -$28K -2,894 Closed
GF
112
Gerstein Fisher
New York
– -$26K -2,667 Closed
Northwestern Mutual Wealth Management
113
Northwestern Mutual Wealth Management
Wisconsin
– -$1K -56 Closed
Fifth Third Bancorp
114
Fifth Third Bancorp
Ohio
– +$127 +8 New
1 2 3 4
5

CASC Hedge Fund Activity: Q2 2015 in Review

100 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q2 2015, worth a combined $211M — up 105% from $103M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new CASC positions and 17 closed out — a net gain of 10 holders — while 38 added to existing stakes and 22 trimmed.

The largest buyer was Redmile Group, opening a new position worth an estimated $11M. The largest seller was BVF Inc, cutting an estimated $12M.

  • 100 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q2 2015, up from 90 in Q1 2015.
  • Funds reported $211M of Cascadian Therapeutics, Inc. stock for Q2 2015, up 105% quarter-over-quarter.
  • 27 funds opened new Cascadian Therapeutics, Inc. positions in Q2 2015 and 17 closed out, a net change of +10 holders.
  • The largest Cascadian Therapeutics, Inc. buyer in Q2 2015 was Redmile Group, an estimated $11M added.
  • The largest Cascadian Therapeutics, Inc. seller in Q2 2015 was BVF Inc, an estimated $12M sold.

Based on aggregated 13F filings for Q2 2015.